fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Itraconazole

All products: Limited Use (codes 570)

Odan-Itraconazole · DIN 02495988 · 10 mg/mL · Oral Sol

Limited Use, Reason for Use code 570 requiredMarketed · checked November 18, 2026
StatusLimited Use, Reason for Use code 570 required
Write on scriptReason for Use code 570 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 570
Reason for Use code 570 For patients who are unable to swallow or tolerate solid oral dosage forms. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Odan-Itraconazole · DIN 02495988 Manufacturer: Odan Laboratories Ltd.; listing date 2020-08-28 Health Canada: Marketed since 2020-07-08 · brand ODAN ITRACONAZOLE · ATC J02AC02 ITRACONAZOLE · form Solution · route Oral · ingredients ITRACONAZOLE 10 MG/ML · company Odan laboratoriesltd · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Odan-Itraconazole: Formulary list price $0.41 per unit (the source does not state the unit; exact figure $0.4111). What the ministry pays, not the patient.

Ministry pays: $0.4111 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02495988)

Source record
DIN 02495988: Odan-Itraconazole Raw flags: sec12=Y, sec3=Y Item: 081204043; group id 11; item number 0014; lccId 00327; manufacturer id ODN Source form: Oral Sol; strength: 10mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.4111; ministry $0.4111 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02495988 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98587
Interchangeable products
Jamp Itraconazole Oral Solution · DIN 02484315 · $0.4111 Sporanox · DIN 02231347 · not recorded
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (J02A, J02AC): coverage varies; not interchangeable

  • Fluconazole (Diflucan P.O.S.): general benefit, limited Use 528, not a benefit
  • Voriconazole (Vfend): limited Use 399
  • Posaconazole (Posanol): not a benefit
  • Amphotericin b (Fungizone): general benefit
  • Ketoconazole (Nizoral): general benefit, not a benefit
  • Caspofungin (Cancidas): not a benefit

1 more in the class list below

Other drugs in the same formulary class (08:12:04 Antifungals) and how they are covered

Matched class: 08:12:04 Antifungals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMPHOTERICIN B Some products covered without a code (check the product listing): FLUCONAZOLE, KETOCONAZOLE, NYSTATIN, TERBINAFINE HCL 08:12:04 Antifungals

FLUCONAZOLE

· 17 products · Limited Use, codes 528 (1), Listed, not a benefit (2), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (12) · strengths: 10mg/mL, 50mg, 100mg · O/L, Tab

VORICONAZOLE

· 6 products · Limited Use, codes 399 · strengths: 50mg, 200mg · Tab

POSACONAZOLE

· 7 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 40mg/mL · DR Tab, O/L

AMPHOTERICIN B

· 1 products · General benefit · strengths: · Inj Pd-50mg Pk

KETOCONAZOLE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 200mg · Tab

CASPOFUNGIN ACETATE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg/Vial · Inj-Vial Pk

MICAFUNGIN SODIUM

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg/Vial, 100mg/Vial · Inj Pd-10mL Vial Pk

NYSTATIN

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 100000U/mL · O/L

TERBINAFINE HCL

· 8 products · Listed, not a benefit (1), General benefit (7) · strengths: 250mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:12:04
Full class listing Related classes: 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS MINT-ITRACONAZOLE (itraconazole) capsules are indicated for: • the treatment of the following systemic fungal infections in normal, predisposed or immunocompromised patients: 1. Invasive and non-invasive pulmonary aspergillosis. 2. Oral and/or esophageal candidiasis. 3. Chronic pulmonary histoplasmosis. 4. Cutaneous and lymphatic sporotrichosis. 5. Paracoccidioidomycosis. 6. Chromoblastomycosis.(formerly chromomycosis) 7. Blastomycosis. The type of organism responsible for the infection should be isolated and identified and other relevant laboratory studies (wet mount, histopathology, serology) should be undertaken as appropriate to confirm diagnosis. Therapy may be initiated prior to obtaining these results when clinically warranted; however, once these results become available, antifungal therapy should be adjusted accordingly. • the treatment of the following topical fungal infections in normal, predisposed or immunocompromised patients: 8. Dermatomycoses due to tinea corporis, tinea cruris, tinea pedis, and pityriasis versicolor, where … https://pdf.hres.ca/dpd_pm/00082400.PDF PM date: OCT 27, 2025 Source product: MINT-ITRACONAZOLE; DIN 02462559; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.